Pfizer Inc. is rated a Buy with stable guidance, robust pipeline, strong free cash flows & appealing dividend yield. Learn ...

Revenue reported by Pfizer in Q3 2025 came in at $16.7 billion, which was another beat compared to the analysts’ estimate of ...

Pfizer has long been a solid dividend payer, having raised its dividend annually for 16 years. The world's oil supply is ...

The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...

Pfizer’s Q3 2025 earnings fell despite beating estimates. Weak growth and a stagnant outlook keep PFE stock a Hold.

Drugmaker Pfizer ($PFE) is set to report its Q3 earnings results on November 4 before the market opens. Analysts are ...

Pfizer offers an annual dividend yield of 6.98%, or $1.72 a year. Here's how investors can pocket a regular $500 monthly.

Pfizer (PFE) shares have seen some moderate movement lately, offering investors a chance to reconsider the company’s ...

Global pharmaceutical company Pfizer (NYSE:PFE) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 5.9% ...

Pfizer files lawsuits against Novo over $9B Metsera bid, challenging 30-month timeline. Court hearing Tuesday as deadline ...

Currently, the analyst consensus on Pfizer is a Hold with an average price target of $28.60, representing a 15.98% upside. In a report released today, J.P. Morgan also maintained a Hold rating on the ...

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...